These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 32640132)

  • 1. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
    Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
    N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
    Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
    J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.
    Kabashima K; Matsumura T; Hayakawa Y; Kawashima M;
    J Dermatolog Treat; 2023 Dec; 34(1):2177096. PubMed ID: 36779675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
    Igarashi A; Katsunuma T; Matsumura T; Komazaki H;
    Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
    Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
    J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.
    Mihara R; Kabashima K; Furue M; Nakano M; Ruzicka T
    J Dermatol; 2019 Aug; 46(8):662-671. PubMed ID: 31166620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):997-1011. PubMed ID: 36905481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
    Silverberg JI; Pinter A; Alavi A; Lynde C; Bouaziz JD; Wollenberg A; Murrell DF; Alpizar S; Laquer V; Chaouche K; Ahmad F; Armstrong JM; Piketty C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1562-1568. PubMed ID: 33711179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
    Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
    Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.